Furthermore, given that the first successful phase 1 clinical trial for MYC inhibitor (OMO-103) was recently published (Garralda et al, 2024), our results suggest a potential impact for combined therapies for cancer that include radiation and MYC inhibition. Here, MYC is linked to cancer.